NeoChord
NeoChord, a medical device company, develops devices that allow mitral valve repair to be performed on a beating heart.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | $2.8m | Convertible | |
| Total Funding | 000k | ||
Related Content
NeoChord, founded in 2007, is a medical technology company based in St. Louis Park, Minnesota. The company is focused on the treatment of degenerative mitral valve regurgitation (DMR) through minimally invasive techniques.
The company has developed a proprietary technology, the NeoChord Artificial Chordae Delivery System. This system is designed to allow for the repair of the mitral valve on a beating heart, which is a significant departure from traditional open-heart surgery. The procedure is performed through a small incision between the ribs and is guided by echocardiography. This approach aims to reduce patient trauma and recovery time compared to conventional methods.
The business model of NeoChord is centered on the development and sale of its medical devices for use in cardiac surgery. The primary clients for its technology are hospitals and cardiac surgeons who treat patients with DMR. By providing a less invasive surgical option, the company addresses a key need in the cardiac care market for safer and more efficient treatment solutions.
Keywords: medical device, mitral valve repair, minimally invasive surgery, cardiac surgery, degenerative mitral valve regurgitation, echo-guided, artificial chordae, beating heart surgery, medical technology, surgical instruments